- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05973968
Surufatinib in G3 Neuroendocrine Tumors
A Real-world Study of Surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors
The goal of this observational study is to learn about surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors. The main questions it aims to answer are:
- To evaluate the efficacy and safety of surufatinib in the treatment of second-line and posterior-line in G3 neuroendocrine tumors.
- To explore the predictive value of blood perfusion parameters in curative effect.
Participants will be given surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, there is a lack of standard treatment for metastatic G3 neuroendocrine tumors, and CSCO guidelines recommend patients to enter clinical trials. The NCCN guidelines recommend that patients with G3 be divided into two groups according to Ki67 > 55%, SSTR expression, tumor load and progression, and are treated with chemotherapy, somatostatin, mTOR inhibitor, and Sunitinib (limited to pancreatic neuroendocrine tumors). Among them, a small sample study showed that there was no significant difference in the efficacy of sunitinib in the treatment of pancreatic neuroendocrine tumors (PFS) between G3 and G1/2.
surufatinib capsule is a new oral tyrosine kinase inhibitor. Approved by NMPA for unresectable locally advanced or metastatic, advanced non-functional, well differentiated (G1, G2) non-pancreatic (December 2020) and pancreatic (June 2021) neuroendocrine tumors, in the 2022 Chinese guidelines for integrated diagnosis and treatment of tumors, it is recommended to choose surufatinib after the second line of treatment for G3 NEN patients with Ki67 < 55%. However, there is still a lack of data on the efficacy and safety of surufatinib in the real world in China, and its efficiency in G3 NEN is worth exploring.
The goal of this observational study is to learn about surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors. The main questions it aims to answer are:
- To evaluate the efficacy and safety of surufatinib in the treatment of second-line and posterior-line in G3 neuroendocrine tumors.
- To explore the predictive value of blood perfusion parameters in curative effect.
Participants will be given surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity.
Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
Safety indicators include: adverse events, laboratory tests, vital signs and changes in ECG and echocardiography.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jian Wang
- Phone Number: +8618560088226
- Email: wang.jian@sdu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have fully understood this study and voluntarily signed the informed consent form;
- Age ≥ 18 years old, both male and female;
- Neuroendocrine tumors diagnosed by histopathology or cytology (patients with neuroendocrine tumors diagnosed as G3 according to WHO2019 criteria, and Ki67 index ≤ 55%);
- Progress after at least one systemic chemotherapy;
- According to the evaluation criteria of solid tumor efficacy (RECISTV1.1), there is at least one measurable lesion.
- Palliative radiotherapy at the localized site was allowed for more than 7 days since the end of the last systematic treatment, which has been over 4 weeks.
- Expected survival ≥ 12 weeks;
- The researchers assessed that they could benefit;
- Have enough organ and bone marrow function;
- Fertile male or female patients voluntarily used effective contraceptive methods during the study period and within 6 months of the last study, such as double barrier contraceptives, condoms, oral or injection contraceptives, intrauterine devices, etc. All female patients will be considered fertile unless the female patient has undergone natural menopause, artificial menopause or sterilization (such as hysterectomy, bilateral adnexectomy or radioactive ovarian irradiation). Otherwise, the serum of female patients showed that they were not pregnant within 7 days before the study and must be non-lactation patients.
Exclusion Criteria:
- Other malignant tumors have been diagnosed in the past 5 years, except for skin basal cell carcinoma, skin squamous cell carcinoma, cervical cancer in situ and breast cancer after effective treatment.
- At the same time, receive other experimental drugs or approved or under research anti-tumor therapy;
- Patients with contraindications of Surufatinib (such as active bleeding, ulcer, intestinal perforation, intestinal obstruction, uncontrollable hypertension, III-IV cardiac insufficiency, severe hepatic and renal insufficiency within 30 days after major operation, etc.).
- The patient currently has any disease or condition that affects drug absorption, or the patient cannot take Surufatinib orally;
- It has been proved to be allergic to experimental drugs and any components in their excipients;
- Women who are pregnant (positive for pre-medication pregnancy test) or breastfeeding;
- Patients with large pleural effusion or ascites need drainage;
- Any other disease, with clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the researchers, there is reason to suspect that the patient has a disease or state that is not suitable for the use of research drugs (such as having seizures and requiring treatment), or will affect the interpretation of the findings or put the patient at high risk;
- Drugs containing Hypericum perforatum were taken within 3 weeks before treatment, or other strong inducers or inhibitors of CYP3A4 were taken in the previous 2 weeks.
- According to the researchers, the subjects have other factors that may lead to the termination of this study or are not suitable for inclusion, such as other serious concomitant diseases (such as severe diabetes, thyroid disease, spinal cord compression, superior vena cava syndrome, mental illness), severe laboratory abnormalities, family or social factors, which will affect the safety of the subjects, or the collection of data and samples.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
surufatinib
Surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity
|
Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1)
or death (during the treatment of the patient).
The treatment and survival status of the tumor after disease progression were recorded.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: through study completion, an average of 1 year
|
Progression Free Survival
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response rate
Time Frame: through study completion, an average of 1 year
|
objective response rate
|
through study completion, an average of 1 year
|
overall survival
Time Frame: through study completion, an average of 1 year
|
overall survival
|
through study completion, an average of 1 year
|
disease control rate
Time Frame: through study completion, an average of 1 year
|
disease control rate
|
through study completion, an average of 1 year
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: through study completion, an average of 1 year
|
Including type, incidence, grading (according to NCI-CTCAEV5.0),
severity.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.
- Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020 Apr 1;41(2):371-403. doi: 10.1210/endrev/bnz004.
- Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. Erratum In: N Engl J Med. 2011 Mar 17;364(11):1082.
- Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
- Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KYLL-202210-028-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumor Grade 3
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbHCompletedNeuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditionsGermany
-
Peking Union Medical College HospitalHarbin Medical University; The First Affiliated Hospital of Xiamen UniversityRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3China
-
Yusuf MendaNational Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...Enrolling by invitationNeuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1United States
-
University of IowaNovartisNot yet recruitingNeuroendocrine Tumors | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1United States
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
University Hospital, Basel, SwitzerlandUniversity Hospital, Zürich; University Hospital Freiburg; Krebsforschung Schweiz... and other collaboratorsRecruitingThyroid Cancer, Medullary | Neuroendocrine Tumor of the Lung Grade 1 and 2 | Neuroendocrine Tumor of the Thymus Grade 1 and 2 | Neuroendocrine Tumor GEP Grade 1-3Switzerland
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyCompletedNeuroendocrine Carcinoma, Grade 3Korea, Republic of
-
Tianjin Medical University Cancer Institute and...RecruitingPancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3China
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); NovartisCompletedIntermediate Grade Lung Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Functional Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Duodenal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor | Nonfunctional Pancreatic Neuroendocrine... and other conditionsUnited States
Clinical Trials on Surufatinib
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
Hutchison Medipharma LimitedCompletedHealthyUnited States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingHead and Neck Cancers - Salivary GlandChina
-
Zhejiang Cancer HospitalRecruitingBile Duct AdenocarcinomaChina
-
Changhai HospitalNot yet recruitingPancreatic Neuroendocrine TumorChina
-
Sun Yat-sen UniversityRecruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityRecruiting
-
Hutchison Medipharma LimitedCompleted